Atlas Genetics Ltd today announces that it has completed development of the Atlas io® Reader, a POC device that can deliver laboratory quality results for molecular assays in under thirty minutes.
The Atlas io® Reader, developed with The Technology Partnership plc (“TTP”), operates with a disposable cartridge, to which an unprocessed clinical specimen is added. The instrument fully automates the three-stage process of sample preparation, DNA amplification, and electrochemical detection to analyse the patient’s sample for the target infection.
The current clinical practice usually involves sending test samples to the central laboratory for analysis with a turn-around time of up to ten days.
The Atlas io® Reader allows rapid diagnosis of infectious diseases, providing clinicians with the opportunity to treat the patient immediately, eliminating the need for a return visit and greatly improving patient outcomes.
The Atlas io® Reader is now entering pilot manufacture ahead of the company conducting clinical studies to support its application for regulatory clearance in Europe later this year.
John Clarkson, CEO of Atlas, said: “Our focus is on diseases including sexually transmitted, and hospital acquired infections, where rapid diagnosis is essential for effective treatment and control. The Atlas io® Reader is an accurate, low cost, diagnostic instrument that has the potential to revolutionise infectious disease diagnosis by allowing clinicians to test and treat their patients in the same visit.”
Piers Harding, project leader at TTP, comments: “The outstanding results that we are seeing from initial production instruments are testament to the close working relationship that Atlas Genetics and TTP have formed over the past year.”
About TTP (www.ttp.com)
The Technology Partnership plc (TTP) is Europe's leading technology and product development company. TTP works closely with its clients to create disruptive products based on advances in technology and engineering innovation. TTP’s technology lies behind many products and processes in areas as diverse as communications, digital printing, instrumentation, consumer & industrial products, biotechnology, medical devices, cleantech and security systems.
Atlas Genetics Ltd today announces the appointment of David Whitaker as Operations Director with immediate effect.
David joins Atlas from DNA Electronics, where he worked as Manufacturing & Mechanical Engineering Manager, responsible for the development of a fully portable, point-of-care genetic test device. This project involved a wide range of technical disciplines including microfluidics, electronics and molecular biology. He worked closely with the acting Chief Scientific Officer on the overall management of the project and held direct responsibility for all device engineering activities.
Prior to this, he spent five years as a Principal Consultant in PA Consulting’s Technology and Innovation Practice. During his tenure, he successfully developed and patented a range of medical devices for both big pharma and start-up companies. Before joining PA Consulting, David worked in a variety of medical device engineering, contract engineering and consulting positions at companies including Ivax Pharmaceuticals, Futura Medical West Pharmaceuticals and Risdon Pharma.
David has First Class BEng degree in Mechanical & Manufacturing Engineering with Management from the University of Leeds.
Dr John Clarkson, Chief Executive Officer of Atlas, commented: “At Atlas, we have worked hard over the past year to enhance and develop our senior management team. David brings considerable operational expertise which will be important as we enter a new phase of product manufacture and growth, further progressing Atlas towards becoming a first class diagnostics company.”